Telomir Pharmaceuticals (NASDAQ:TELO) Posts Earnings Results

Telomir Pharmaceuticals (NASDAQ:TELO) posted its earnings results on Thursday. The company reported ($0.79) earnings per share for the quarter, Zacks reports.

Telomir Pharmaceuticals Stock Down 5.4%

TELO stock traded down $0.06 during trading on Thursday, hitting $1.05. The company had a trading volume of 86,652 shares, compared to its average volume of 126,949. The firm has a market capitalization of $72.22 million, a P/E ratio of -3.62 and a beta of -0.24. Telomir Pharmaceuticals has a 52-week low of $0.89 and a 52-week high of $2.09. The company has a 50 day simple moving average of $1.22 and a 200-day simple moving average of $1.26.

Institutional Trading of Telomir Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Bank of America Corp DE grew its stake in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after purchasing an additional 10,880 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Telomir Pharmaceuticals during the 2nd quarter valued at $33,000. XTX Topco Ltd bought a new stake in Telomir Pharmaceuticals during the 4th quarter valued at $53,000. Jane Street Group LLC purchased a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth $62,000. Finally, Raymond James Financial Inc. grew its position in shares of Telomir Pharmaceuticals by 4,101.9% during the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after buying an additional 73,547 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.